Morgan Stanley
TRAX

Morgan Stanley’s First Tracks Biotherapeutics TRAX Stock Holding History

Morgan Stanley’s Portfolio TRAX Stock Details TRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7M Buy
+781,534
New +$14.6M ﹤0.01% 3307

Other funds holding TRAX

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley's TRAX Position: Q2 2026 in Review

Morgan Stanley opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 781,534 shares worth $15.7M. The stake represents ﹤0.01% of the portfolio and ranks #3307 among its holdings.

89 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

  • Morgan Stanley held 781,534 shares of First Tracks Biotherapeutics worth $15.7M as of Q2 2026.
  • First Tracks Biotherapeutics was a new Morgan Stanley position in Q2 2026.
  • First Tracks Biotherapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #3307 holding.
  • 89 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.